Middlefield Healthcare&Life Sciences ETF (LS.TO)

11.07 +0.00  +0.00% TSX Feb 21, 20:00 Delayed 15m CAD
View Full Chart
Price Chart

Key Stats

Net Asset Value 11.07
Discount or Premium to NAV 0.01%
Turnover Ratio 40.32%
1 Year Fund Level Flows --

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 0.73% 0.55% -- --
3M 6.02% 5.79% -- --
6M 8.40% 8.42% -- --
YTD 4.63% 4.33% -- --
1Y 7.10% 7.56% -- --
3Y -- -- -- --
5Y -- -- -- --
10Y -- -- -- --
15Y -- -- -- --
20Y -- -- -- --
As of Feb. 21, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 4.24% 4.24% 0.00%
Stock 95.76% 95.76% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Dec. 31, 2019

Region Exposure

Americas 81.42%
North America 81.42%
Latin America 0.00%
Greater Europe 18.42%
United Kingdom 6.09%
Europe Developed 11.75%
Europe Emerging 0.00%
Africa/Middle East 0.57%
Greater Asia 0.16%
Japan 0.00%
Australasia 0.16%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.00%
% Emerging Markets --
As of Dec. 31, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 92.21%
Industrials 0.00%
Real Estate 7.79%
Technology 0.00%
Utilities 0.00%
As of Dec. 31, 2019

Stock Market Capitalization

Giant 38.84%
Large 33.96%
Medium 8.94%
Small 16.77%
Micro 1.49%
As of Dec. 31, 2019

Stock Style Exposure

Large Cap Value 8.59%
Large Cap Blend 40.07%
Large Cap Growth 25.86%
Mid Cap Value 0.00%
Mid Cap Blend 5.00%
Mid Cap Growth 4.15%
Small Cap Value 2.74%
Small Cap Blend 6.88%
Small Cap Growth 6.72%
As of Dec. 31, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
TMO Thermo Fisher Scientific Inc 3.73% 334.94 -0.33%
UNH UnitedHealth Group Inc 3.38% 301.43 -0.23%
VRTX Vertex Pharmaceuticals Inc 3.24% 246.29 +0.49%
BDX Becton, Dickinson and Co 3.13% 257.35 +1.53%
ISRG Intuitive Surgical Inc 2.91% 613.08 -0.84%
AMGN Amgen Inc 2.77% 222.79 +0.29%
SYK Stryker Corp 2.76% 224.30 -0.08%
NSTG NanoString Technologies Inc 2.74% 33.41 +0.33%
EW Edwards Lifesciences Corp 2.68% 231.25 -1.14%
ROG Roche Holding AG Dividend Right Cert. 2.66% -- --
As of Dec. 31, 2019
Advertisement

Basic Info

Investment Strategy
The investment objectives of Life Sciences are to provide holders of Life Sciences Units with: (a) stable monthly cash distributions; and (b) enhanced long-term total return through capital appreciation of the Life Sciences investment portfolio through an investment strategy that focuses primarily on investing in dividend-paying securities of issuers operating in, or that derive a significant portion of their revenue or earnings from, products or services related to the healthcare, life sciences and related industries.
General
Security Type Exchange-Traded Fund
Equity Style Large Cap/Growth
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Prospectus Objective --
Fund Owner Firm Name Middlefield Limited
Benchmark Index
MSCI Daily TR World Net HC NR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Not Disclosed 2.28 yrs

Net Fund Flows

1M 0.00
3M 7.712M
6M 6.423M
YTD 0.00
1Y --
3Y --
5Y --
10Y --
As of Jan. 31, 2020

Risk Info

Beta (5Y) --
Max Drawdown (All) 9.05%
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) --
30-Day Rolling Volatility 11.82%
Daily Value at Risk (VaR) 1% (All) 2.24%
Monthly Value at Risk (VaR) 1% (All) 6.75%

Fundamentals

Dividend Yield TTM (2-21-20) 3.39%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 28.74
Weighted Average Price to Sales Ratio 4.740
Weighted Average Price to Book Ratio 4.554
Weighted Median ROE 17.31%
Weighted Median ROA 1.65%
Forecasted Dividend Yield 1.53%
Forecasted PE Ratio 20.28
Forecasted Price to Sales Ratio 4.343
Forecasted Price to Book Ratio 4.056
Number of Holdings 55
As of Dec. 31, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 9.70%
Forecasted Book Value Growth 4.37%
Forecasted Cash Flow Growth 3.74%
Forecasted Earnings Growth 34.52%
Forecasted Revenue Growth 4.59%
As of Dec. 31, 2019

Comparables

Edit

Attributes

Key Dates
Inception Date 7/21/2017
Termination Date
Last Annual Report Date 12/31/2018
Last Prospectus Date
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.